New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...

Columnist Ann Reynoso may have looked well during a recent holiday gathering, but living with PF meant she was battling ...

Columnist Sam Kirton explores what options are available to help IPF patients meet the costs of their medical care and medications.

The gut bacteria B. adolescentis eased lung scarring in a pulmonary fibrosis mouse model, showing potential as a preventive ...

When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in the early days of 2017, it seemed like my world moved in slow motion. Just a few months earlier, as my diagnostic journey began in the ...

What is Jascayd for pulmonary fibrosis? Jascayd (nerandomilast) is an approved oral therapy that’s intended to slow lung function decline in adults with idiopathic pulmonary fibrosis (IPF) and ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...